Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Liver Cirrhosis

  Free Subscription


Articles published in J Gastroenterol

Retrieve available abstracts of 44 articles:
HTML format



Single Articles


    March 2024
  1. WANG J, Zhang H, Chen L, Fu K, et al
    CircDCBLD2 alleviates liver fibrosis by regulating ferroptosis via facilitating STUB1-mediated PARK7 ubiquitination degradation.
    J Gastroenterol. 2024;59:229-249.
    PubMed     Abstract available


    February 2024
  2. NAMISAKI T, Sato S, Yoshiji H
    Role of combined aerobic and resistance exercise in liver cirrhosis.
    J Gastroenterol. 2024 Feb 8. doi: 10.1007/s00535-024-02078.
    PubMed    


    January 2024
  3. KOBAYASHI T, Iwaki M, Nogami A, Kawamura N, et al
    Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography.
    J Gastroenterol. 2024;59:56-65.
    PubMed     Abstract available


    December 2023
  4. KAWAGUCHI T, Kawaguchi A, Hashida R, Nakano D, et al
    Resistance exercise in combination with aerobic exercise reduces the incidence of serious events in patients with liver cirrhosis: a meta-analysis of randomized controlled trials.
    J Gastroenterol. 2023 Dec 30. doi: 10.1007/s00535-023-02060.
    PubMed     Abstract available


  5. ICHITA C, Goto T, Shimizu S
    Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data.
    J Gastroenterol. 2023 Dec 19. doi: 10.1007/s00535-023-02066.
    PubMed    


  6. UENO M, Fujiwara T, Tokumasu H, Mizuno M, et al
    Reply to "Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data".
    J Gastroenterol. 2023 Dec 13. doi: 10.1007/s00535-023-02067.
    PubMed    


  7. UOJIMA H, Nakabayashi K, Yamasaki K, Sugiyama M, et al
    New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer in chronic liver disease.
    J Gastroenterol. 2023;58:1252-1260.
    PubMed     Abstract available


    October 2023
  8. WANG H, Li Y, Pu X, Liang X, et al
    MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
    J Gastroenterol. 2023 Oct 16. doi: 10.1007/s00535-023-02045.
    PubMed     Abstract available


  9. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
    Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
    J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02039.
    PubMed     Abstract available


    September 2023
  10. WEI M, Chen Y, Wang M, Li J, et al
    Correction: Partial splenic embolization combined with endoscopic therapies and vasoconstrictive drugs reduces rebleeding in cirrhosis patients with acute variceal bleeding and hypersplenism: a multicenter randomized controlled trial.
    J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02036.
    PubMed    


  11. JIANG K, Lu S, Li D, Liu M, et al
    Blockade of C5aR1 alleviates liver inflammation and fibrosis in a mouse model of NASH by regulating TLR4 signaling and macrophage polarization.
    J Gastroenterol. 2023;58:894-907.
    PubMed     Abstract available


    July 2023
  12. WEI M, Chen Y, Wang M, Li J, et al
    Partial splenic embolization combined with endoscopic therapies and vasoconstrictive drugs reduces rebleeding in cirrhosis patients with acute variceal bleeding and hypersplenism: a multicenter randomized controlled trial.
    J Gastroenterol. 2023 Jul 24. doi: 10.1007/s00535-023-02027.
    PubMed     Abstract available


    May 2023
  13. KIM KA, Choi HY, Ki M, Jang ES, et al
    Epidemiological trends and outcomes of primary biliary cholangitis in South Korea between 2009 and 2019.
    J Gastroenterol. 2023 May 17. doi: 10.1007/s00535-023-01999.
    PubMed     Abstract available


  14. UENO M, Fujiwara T, Tokumasu H, Mano T, et al
    Real-world efficacy of antibiotic prophylaxis for upper gastrointestinal bleeding in cirrhotic patients in Japan.
    J Gastroenterol. 2023 May 12. doi: 10.1007/s00535-023-02000.
    PubMed     Abstract available


  15. YE MP, Lu WL, Rao QF, Li MJ, et al
    Mitochondrial stress induces hepatic stellate cell activation in response to the ATF4/TRIB3 pathway stimulation.
    J Gastroenterol. 2023 May 7. doi: 10.1007/s00535-023-01996.
    PubMed     Abstract available


    April 2023
  16. NAKAI M, Morikawa K, Sasaki T, Kohya R, et al
    Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis.
    J Gastroenterol. 2023 Apr 27. doi: 10.1007/s00535-023-01993.
    PubMed     Abstract available


    March 2023
  17. GAO TM, Zhou J, Xiang XX, Jin SJ, et al
    plenectomy and azygoportal disconnection decreases the risk of hepatocellular carcinoma for cirrhosis patients with portal hypertension bleeding: a 10-year retrospective follow-up study based on the inverse probability of treatment weighting method.
    J Gastroenterol. 2023 Mar 21. doi: 10.1007/s00535-023-01982.
    PubMed     Abstract available


  18. CHANG X, Li Y, Sun C, Li X, et al
    High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy.
    J Gastroenterol. 2023 Mar 16. doi: 10.1007/s00535-023-01970.
    PubMed     Abstract available


  19. MA L, Liu Y, Yan Z, Zhang W, et al
    Comparing the predictive ability of portoatrial and portocaval gradient after transjugular intrahepatic portosystemic shunt creation for variceal rebleeding.
    J Gastroenterol. 2023 Mar 9. doi: 10.1007/s00535-023-01977.
    PubMed     Abstract available


    February 2023
  20. KOTANI K, Enomoto M, Uchida-Kobayashi S, Tamori A, et al
    Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis.
    J Gastroenterol. 2023 Feb 2. doi: 10.1007/s00535-023-01963.
    PubMed     Abstract available


  21. KAMADA Y, Nakamura T, Isobe S, Hosono K, et al
    SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum.
    J Gastroenterol. 2023;58:79-97.
    PubMed     Abstract available


    January 2023
  22. ZHANG X, Durham KM, Garza AA, Murali AR, et al
    Portal vein thrombosis, hepatic decompensation, and survival in patients with porto-sinusoidal vascular disease and portal hypertension.
    J Gastroenterol. 2023 Jan 24. doi: 10.1007/s00535-023-01957.
    PubMed     Abstract available


  23. SAKAI N, Kamimura K, Miyamoto H, Ko M, et al
    Letrozole ameliorates liver fibrosis through the inhibition of the CTGF pathway and 17beta-hydroxysteroid dehydrogenase 13 expression.
    J Gastroenterol. 2023;58:53-68.
    PubMed     Abstract available


    November 2022
  24. LIAW YF
    Perspectives on current controversial issues in the management of chronic HBV infection.
    J Gastroenterol. 2022;57:828-837.
    PubMed     Abstract available


  25. LIN YC, Lin HF, Wu CC, Chen CL, et al
    Pathogenic effects of Desulfovibrio in the gut on fatty liver in diet-induced obese mice and children with obesity.
    J Gastroenterol. 2022;57:913-925.
    PubMed     Abstract available


    September 2022
  26. HANAI T, Nishimura K, Miwa T, Maeda T, et al
    A shortened Stroop test to identify covert hepatic encephalopathy and predict overt hepatic encephalopathy in patients with cirrhosis.
    J Gastroenterol. 2022 Sep 29. pii: 10.1007/s00535-022-01925.
    PubMed     Abstract available


    July 2022
  27. OKUSHIN K, Tateishi R, Takahashi A, Uchino K, et al
    Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL).
    J Gastroenterol. 2022 Jul 5. pii: 10.1007/s00535-022-01893.
    PubMed     Abstract available


    May 2022
  28. AMPUERO J, Gallego-Duran R, Maya-Miles D, Montero R, et al
    Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD.
    J Gastroenterol. 2022;57:357-371.
    PubMed     Abstract available


    January 2022
  29. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
    Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis.
    J Gastroenterol. 2022 Jan 20. pii: 10.1007/s00535-021-01845.
    PubMed     Abstract available


    December 2021
  30. BURGHART L, Halilbasic E, Schwabl P, Simbrunner B, et al
    Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis.
    J Gastroenterol. 2021 Dec 11. pii: 10.1007/s00535-021-01839.
    PubMed     Abstract available


  31. NAKAYAMA N, Uemura H, Uchida Y, Imai Y, et al
    Nationwide survey for patients with acute-on-chronic liver failure occurring between 2017 and 2019 and diagnosed according to proposed Japanese criteria.
    J Gastroenterol. 2021;56:1092-1106.
    PubMed     Abstract available


    November 2021
  32. MATSUMOTO K, Ohfuji S, Abe M, Komori A, et al
    Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case-control study.
    J Gastroenterol. 2021 Nov 18. pii: 10.1007/s00535-021-01836.
    PubMed     Abstract available


    September 2021
  33. HANAI T, Nishimura K, Miwa T, Maeda T, et al
    Usefulness of nutritional therapy recommended in the Japanese Society of Gastroenterology/Japan Society of Hepatology evidence-based clinical practice guidelines for liver cirrhosis 2020.
    J Gastroenterol. 2021 Sep 17. pii: 10.1007/s00535-021-01821.
    PubMed     Abstract available


    July 2021
  34. YOSHIJI H, Nagoshi S, Akahane T, Asaoka Y, et al
    Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.
    J Gastroenterol. 2021 Jul 7. pii: 10.1007/s00535-021-01788.
    PubMed     Abstract available


    May 2021
  35. ITAKURA J, Kurosaki M, Setoyama H, Simakami T, et al
    Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis.
    J Gastroenterol. 2021;56:470-478.
    PubMed     Abstract available


    March 2021
  36. ENOMOTO H, Nishiguchi S
    Reply to the letter by Huo et al. regarding our manuscript "The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan".
    J Gastroenterol. 2021 Mar 11. pii: 10.1007/s00535-021-01768.
    PubMed    


    February 2021
  37. ISHIKAWA T, Sasaki R, Nishimura T, Matsuda T, et al
    Splenic non-infarction volume determines a clinically significant hepatic venous pressure gradient response to partial splenic embolization in patients with cirrhosis and hypersplenism.
    J Gastroenterol. 2021 Feb 24. pii: 10.1007/s00535-021-01762.
    PubMed     Abstract available


    November 2020
  38. ENOMOTO H, Ueno Y, Hiasa Y, Nishikawa H, et al
    The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan.
    J Gastroenterol. 2020 Nov 20. pii: 10.1007/s00535-020-01748.
    PubMed     Abstract available


    October 2020
  39. TAHATA Y, Hikita H, Mochida S, Kawada N, et al
    Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
    J Gastroenterol. 2020 Oct 1. pii: 10.1007/s00535-020-01733.
    PubMed     Abstract available


    September 2020
  40. HIRAMINE Y, Uto H, Mawatari S, Kanmura S, et al
    Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites.
    J Gastroenterol. 2020 Sep 21. pii: 10.1007/s00535-020-01727.
    PubMed     Abstract available


    August 2020
  41. ALI AH, Bi Y, Machicado JD, Garg S, et al
    The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: the Mayo Clinic experience.
    J Gastroenterol. 2020 Aug 8. pii: 10.1007/s00535-020-01714.
    PubMed     Abstract available


    January 2020
  42. KAJI K, Yoshiji H
    Can portal hypertension and hepatic decompensation be predicted?
    J Gastroenterol. 2020 Jan 21. pii: 10.1007/s00535-020-01669.
    PubMed    


    October 2019
  43. ENOOKU K, Tsutsumi T, Kondo M, Fujiwara N, et al
    Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.
    J Gastroenterol. 2019 Oct 10. pii: 10.1007/s00535-019-01633.
    PubMed     Abstract available


    September 2019
  44. KIM D, Kim W, Joo SK, Han J, et al
    Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis.
    J Gastroenterol. 2019 Sep 18. pii: 10.1007/s00535-019-01628.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.